Evidence-Based Medical News

Mode

All Oncology Infectious Disease Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Primary Care & Family Medicine Gastroenterology Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Anesthesiology & Pain Medicine Genetics & Precision Medicine Pulmonology & Critical Care Physical Medicine & Rehab Urology Nephrology Emergency Medicine Ophthalmology Hematology Dermatology Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

regorafenib

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of regorafenib

31 trials tracked of regorafenib: 5 in phase 3 or 4 and 4 with published results. The most-cited published study has 566 citations.

31Trials tracked

5Phase 3 & 4

0Recruiting

4With published results

Phase distribution

Phase 3 5 Phase 2 22 Phase 1 3 Other / NA 1

Phase 3 A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) Completed · 566 cited
Phase 3 (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST Completed · 113 cited
Phase 3 Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) Completed · 95 cited
Phase 3 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007) Completed · 14 cited
Phase 3 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study Completed
Phase 2 A Study of Regorafenib in Advanced Pancreatic Cancer Patients Completed

Show 25 more trials

Phase 2 Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma Completed
Phase 2 Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477) Completed
Phase 2 A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed
Phase 2 Phase II Study of Perindopril and Regorafenib in mCRC Completed
Phase 2 SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes Completed
Phase 2 Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer Completed
Phase 2 An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread Completed
Phase 2 Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Completed
Phase 2 A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer Completed
Phase 2 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Completed
Phase 2 A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy Completed
Phase 2 Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer Completed
Phase 2 Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer Completed
Phase 2 Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases Completed
Phase 2 An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Completed
Phase 2 Single Agent Regorafenib in Refractory Advanced Biliary Cancers Completed
Phase 2 Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma Completed
Phase 2 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations Completed
Phase 2 FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer Completed
Phase 2 Regorafenib in Metastatic Colorectal Cancer Completed
Phase 2 Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer Completed
Phase 1 Regorafenib and Nivolumab Simultaneous Combination Therapy Completed
Phase 1 Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST Completed
Phase 1 To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer Completed
N/A [18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib Completed

Showing the 31 most-cited and recently-updated of 31 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.